Racial, Ethnic Disparities Present in Pediatric Brain Cancer Survival
Black and Hispanic pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or consolidation trials.
Data suggests access to clinical trials alone may not be sufficient in providing equitable care.
Black and Hispanic pediatric patients with high-risk neuroblastoma experienced lower overall survival (OS) rates, per data from a retrospective cohort study published in JAMA Network Open.1
Among patients who were included in induction/consolidation trials, the 5-year OS rate was 47.2% and 61.3% for patients who were Hispanic and White, respectively (HR, 1.55; 95% CI, 1.11-2.15; P = .047). Per multivariate analysis adjusting for factors including MYCN amplification, tumor histology, and International Neuroblastoma Staging System (INSS) stage, investigators noted worse OS outcomes for Hispanic populations compared with White populations (HR, 1.78; 95% CI, 1.25-2.53; P = .01).
Regarding patients who participated in postconsolidation setting trials, univariate analysis revealed significantly worse event-free survival (EFS) outcomes (P = .01) for non-Hispanic Black patients (HR, 1.37; 95% CI, 1.05-1.79) and Hispanic patients (HR, 1.56; 95% CI, 1.14-2.15) compared with White patients. When adjusting for tumor histology, INSS stage, and end-of-induction (EOI) disease response, multivariate analysis showed significantly worse EFS outcomes for Hispanic patients than White patients (HR, 1.68; 95% CI, 1.14-2.47; P = .02).
Five-year OS rates were 67.7% for Black patients, 62.2% for Hispanic patients, and 75.7% for White patients. Compared with White populations, data showed significantly worse OS outcomes per univariate analysis (P < .001) for Black patients (HR, 1.65; 95% CI, 1.23-2.22) and Hispanic patients (HR, 1.73; 95% CI, 1.21-2.47). Additionally, multivariate analysis adjusting for stage and EOI response revealed significantly shorter OS (P = .009) for Black (HR, 1.54; 95% CI, 1.13-2.11) and Hispanic patients (HR, 1.63; 95% CI, 1.09-2.43) compared with White patients.
“The findings show that access to clinical trials alone is insufficient to overcome the inferior survival outcomes experienced by Black and Hispanic children with cancer,” lead study author Puja Umaretiya, MD, MS, assistant professor of pediatrics in the Division of Hematology and Oncology and a member of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, stated in a press release on these findings.2 “While further work is needed to understand disparate survival outcomes, any efforts to improve outcomes for children with cancer will likely need to focus on health-related social needs, which are highly prevalent and may contribute to worse outcomes in Black and Hispanic children.”
Investigators of this retrospective study collected data from COG high-risk neuroblastoma trials conducted between January 1, 2007, and December 31, 2016; a data freeze occurred on June 30, 2021. The study included 2 patient cohorts: those who participated in an induction or consolidation setting trial, and those who participated in a postconsolidation setting trial.
The primary exposures of interest were race and ethnicity, with investigators categorizing patients as Hispanic; non-Hispanic Black; non-Hispanic other, which included those who were American Indian or Alaska Native, Asian, and Native Hawaiian or Other Pacific Islander; and non-Hispanic White. The study’s primary end points were EFS and OS. Secondary end points were care delivery points believed to have mechanically affected disparate survival outcomes, which included factors such as induction delay, early trial withdrawal, relapse or progression as first event, and early phase trial enrollment among those experiencing relapse or progression.
The induction/consolidation cohort included 696 patients who were mostly White (n = 481), followed by Black (n = 109), Hispanic (n = 79), and other races (n = 27). Disproportionate household poverty exposure (P < .001) was noted in patients who were Hispanic (58.2%) and Black (50.5%) compared with those who were White (25.2%).
Investigators included 935 patients in the postconsolidation cohort, with most being White (n = 662), followed by Black (n = 145), Hispanic (n = 87), and other races (n = 41). Correlations between race and ethnicity and poverty and rurality measures in the postconsolidation cohort mirrored those in the induction/consolidation cohort.
No significant differences in induction therapy duration or early trial withdrawal by race and ethnicity occurred. Additionally, investigators observed no significant differences by race and ethnicity for relapse and progression across the induction/consolidation and postconsolidation trials.
The 5-year cumulative incidence of death in induction/consolidation trials was 5.9%, 4.6%, 9.5%, and 16.2% for patients who were White, Black, Hispanic, and other races, respectively, which revealed significant differences by race and ethnicity (P = .049). Across the postconsolidation trials, the 5-year cumulative incidence of death was 0.8%, 5.9%, 2.5%, and 2.4% in each racial and ethnic population (P = .001).
OS from time of first relapse showed significant differences across racial and ethnic populations (P = .04). No significant differences by race and ethnicity were noted for the characteristics of patients who experienced relapse or for enrollment in early-phase trials after relapse.
“These data identify the need for studies focused in 2 areas. First, we need to be thoughtful about the data we collect in clinical trials to understand why marginalized groups do not experience the same outcomes,” Umaretiya stated.2 “Collecting more specific data, such as social determinants of health, may provide insight into the underlying causes. Simultaneously, we need to embed supportive care interventions for groups at risk for worse outcomes despite standardized therapies.”
References
- Umaretiya PJ, Naranjo A, Zhang FF, et al. Racial and ethnic survival disparities among children with high-risk neuroblastoma: a Children’s Oncology Group report. JAMA Network Open. 2025;8(2):e2458531. doi:10.1001/jamanetworkopen.2024.58531
- Differences in survival persist despite access to cancer clinical trials. News release. UT Southwestern Medical Center. April 29, 2025. Accessed May 1, 2025. https://tinyurl.com/2jyj9932
